MA

Interim Management Statement Q3 2021 of Molecular Partners: Advancement of COVID-19 Clinical Program and Continued Immuno-Oncology Momentum

Thursday, October 28, 2021 - 6:00am

53 LR:

Key Points: 
  • 53 LR:
    Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPintherapeutics, today announced its interim management statement for the quarter ending September 30, 2021.
  • COVID-19 continues to be a major concern globally, and a main focus of our efforts at Molecular Partners.
  • Having now enrolled over 700 patients across two global late stage studies, we have accomplished much and are approaching two significant milestones.
  • Molecular Partners collaboration partner, Novartis, is conducting the clinical trial for ensovibep, with Molecular Partners as a sponsor.

ATN Reports Third Quarter 2021 Results

Wednesday, October 27, 2021 - 10:05pm

BEVERLY, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- ATN International, Inc. (Nasdaq: ATNI) today reported results for the third quarter and nine months ended September 30, 2021.

Key Points: 

Debora A. Plunkett elected to Board of Directors of Mercury Systems; William K. O’Brien appointed Chairman of the Board with retirement of Vincent Vitto

Wednesday, October 27, 2021 - 9:15pm

Mercury also announced that Vincent Vitto, Chairman of the Board, retired from the Board effective with the annual meeting on October 27, 2021, and current director, William K. OBrien has been appointed as new Chairman.

Key Points: 
  • Mercury also announced that Vincent Vitto, Chairman of the Board, retired from the Board effective with the annual meeting on October 27, 2021, and current director, William K. OBrien has been appointed as new Chairman.
  • Mr. Vitto, the former President and CEO of the Charles Stark Draper Laboratory and former Vice Chairman of the Defense Science Board, joined the Mercury Board in 2006.
  • He was elected Chairman of the Board in 2010 and has chaired the Nominating and Governance Committee.
  • Mr. OBrien, former Chairman of Enterasys Networks, has served on the Mercury Board of Directors since 2008, including as Chairman of the Audit Committee.

Brookline Bancorp Announces Third Quarter Results

Wednesday, October 27, 2021 - 9:05pm

BOSTON, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Brookline Bancorp, Inc. (NASDAQ: BRKL) (the “Company”) today announced net income of $28.8 million, or $0.37 per basic and diluted share, for the third quarter of 2021, compared to net income of $31.6 million, or $0.40 per basic and diluted share, for the second quarter of 2021, and net income of $18.7 million, or $0.24 per basic and diluted share, for the third quarter of 2020.

Key Points: 

Checkmate Pharmaceuticals Announces CEO Transition

Wednesday, October 27, 2021 - 9:30pm

CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (Checkmate), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman has been appointed as interim President and CEO.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (Checkmate), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman has been appointed as interim President and CEO.
  • Mr. Fuhrman succeeds Barry Labinger, who has transitioned from his roles as President and CEO and Director.
  • Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer.
  • The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information.

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wednesday, October 27, 2021 - 9:05pm

In connection with the appointment, the Compensation Committee of the Board of Directors of Mersana Therapeutics approved a stock option grant to Dr. Bala as an inducement material to Dr. Bala entering into employment with Mersana Therapeutics, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • In connection with the appointment, the Compensation Committee of the Board of Directors of Mersana Therapeutics approved a stock option grant to Dr. Bala as an inducement material to Dr. Bala entering into employment with Mersana Therapeutics, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer.
  • UpRi is also being studied in the expansion portion of a Phase 1 proof-of-concept clinical study.
  • The Company routinely posts information that may be useful to investors on the Investors and Media section of our website at www.mersana.com.

SOPHiA GENETICS to Report Third Quarter 2021 Financial Results on November 10, 2021

Wednesday, October 27, 2021 - 9:05pm

BOSTON and LAUSANNE, Switzerland, Oct. 27, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH) today announced it will report financial results for the third quarter of 2021 before market open on Wednesday, November 10, 2021.

Key Points: 
  • BOSTON and LAUSANNE, Switzerland, Oct. 27, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH) today announced it will report financial results for the third quarter of 2021 before market open on Wednesday, November 10, 2021.
  • The companys management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 2:30 p.m. Central European Time to discuss its results, business developments, and outlook.
  • SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research.
  • The SOPHiA DDM Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally.

CPS Technologies Corporation Announces Third Quarter 2021 Results

Wednesday, October 27, 2021 - 9:01pm

NORTON, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- CPS Technologies Corporation (NASDAQ:CPSH) today announced revenues of $5.5 million and an operating loss of $88 thousand for the quarter ended September 25, 2021.

Key Points: 
  • NORTON, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- CPS Technologies Corporation (NASDAQ:CPSH) today announced revenues of $5.5 million and an operating loss of $88 thousand for the quarter ended September 25, 2021.
  • Michael McCormack, President and CEO, said: Revenues in the third quarter 2021 showed significant improvement over revenues in the third quarter of 2020, reflecting the lessening impact of the Covid-19 pandemic on our business.
  • Revenues in the third quarter 2021 were 24% higher than the third quarter 2020, and our 2021 bookings are 158% of shipments, reflecting our current and expected future growth.
  • Without these expenses CPS would have been solidly profitable in the third quarter.

NEWPRO Home Solutions Honors Local Veteran with Free Bath Makeover in Recognition of Veterans Day for the Fifth Year in A Row

Wednesday, October 27, 2021 - 6:25pm

This is our fifth year participating and providing this gift to a deserving veteran in New England.

Key Points: 
  • This is our fifth year participating and providing this gift to a deserving veteran in New England.
  • At NEWPRO, giving back is part of our core values and at the foundation of our business.
  • In honor of Veterans Day this year, the NEWPRO expert installation team will be crashing the bath of the selected veterans at their home in Andover, MA on November 4.
  • NEWPRO Home Solutions is a three-generation, same family-owned and operated local business providing home improvement solutions to homeowners throughout New England for more than 75 years.